Back to Search
Start Over
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
- Source :
-
Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Dec 20; Vol. 7 (1), pp. 354. Date of Electronic Publication: 2019 Dec 20. - Publication Year :
- 2019
-
Abstract
- The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.
- Subjects :
- Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological adverse effects
Carcinoma, Renal Cell etiology
Disease Management
Humans
Immunotherapy
Kidney Neoplasms etiology
Neoplasm Staging
Practice Guidelines as Topic
Antineoplastic Agents, Immunological therapeutic use
Biomarkers, Tumor
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell pathology
Kidney Neoplasms drug therapy
Kidney Neoplasms pathology
Molecular Targeted Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2051-1426
- Volume :
- 7
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal for immunotherapy of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 31856918
- Full Text :
- https://doi.org/10.1186/s40425-019-0813-8